Proactive Investors - Run By Investors For Investors

ANGLE liquid biopsy yields predictive results in colorectal cancer

The results of a study are to be presented to the prestigious American Society of Clinical Oncology in Chicago
ANGLE liquid biopsy yields predictive results in colorectal cancer
Small samples of blood are able to yield tell-tale signs of cancer

Med-tech firm ANGLE PLC (LON:AGL, OTCQX:ANPCY) has uncovered another potential use of its liquid biopsy system building on the success it has already had isolating and identifying tell-tale signs of breast, head and neck cancers.

The results of a study to be presented to the prestigious American Society of Clinical Oncology in Chicago point to a potential use in the colorectal cancer.

Researchers at the University of Texas MD Anderson Cancer Center used ANGLE’s Parsortix system to harvest circulating tumour cells in patients with the disease.

What they were looking for meEGFR biomarkers within the cells. It is thought patients with said genetic characteristic respond less well to a form of treatment called an EGFR inhibitor.

The MD Anderson study found those with the markers had shorter progression-free survival rates than those without.

Growing body of evidence

"This colorectal cancer study adds to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market,” said ANGLE chief executive Andrew Newland.

“The ability to assess the patient's likely response to a particular drug as a companion diagnostic is a key element in the drive to provide precision medicine for patients saving money and improving treatment."

ANGLE invented and developed the revolutionary Parsortix system, which can detect the early signs of cancer from small samples of blood by identifying the presence of tiny circulating tumour cells.

Parsortix is the centre-piece in two clinical studies in ovarian cancer: ANG-001 in Europe (200 patients) and ANG-003 in the United States (200 patients).

The headline data following a statistical evaluation of the predictive power of the device should be available sometime this quarter, the firm said last month.

ANG-002, assessing Parsortix’s role in detecting metastatic breast cancer, remains on track for completion by the end of the calendar year, it added.  

WATCH: Our last chat with the boss

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
Dog skeleton with cannabis plant leaf
The company's lead drug candidate is a cannabis-derived canine pain medication.
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use